VivoSeq
Gastroenterology

Esophageal Varices

14

Pipeline Programs↗

2

Active Trials↗

9

Companies Involved↗

Esophageal Varices is an emerging landscape with 14 programs across 9 companies. The most active players are Galectin Therapeutics Inc., Salix, Auson Pharmaceuticals Inc.. 5 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

41/100

Pipeline Velocity

0/100

Mech. Concentration

25/100

Completion Rate

82/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Galectin Therapeutics Inc.

1 program

Phase 3S

Salix

1 program

Phase 3A

Auson Pharmaceuticals Inc.

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3Akero Therapeutics logo

Akero Therapeutics

1 program

ApprovedSun Pharma logo

Sun Pharma

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

16 of 17 classified programs — the dominant modality here.

6%ALL OTHERSPeptide16%

Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 94% of 18 pipeline programs.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Unknown status7 · 35%
Recruiting2 · 10%
Terminated2 · 10%

Clinical Trials

Trial Activity

20 trials

Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Recruiting·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01212250·132 enrolled
Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of Oesophageal Varices Trial.
Recruiting·KKing's College Hospital NHS Trust·Phase 4·NCT05872698·1,200 enrolled
Prevention of Esophageal Varices by Beta-Adrenergic Blockers
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 3·NCT00006398·213 enrolled
A Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection for Esophageal Varices
Completed·FFederal University of São Paulo·Phase 4·NCT00799851·38 enrolled
PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)
Completed·—·Phase 4·NCT03175731·106 enrolled
Efficacy and Safety of Endoscopic Injection of Fibrin Sealant Versus Endoscopic Ligature for Bleeding Esophageal Varices
Completed·BBaxter Healthcare Corporation·Phase 3·NCT00161915
Impact of Antiviral Therapy on Gastroesophageal Varices.
Completed·PParc de Salut Mar·N/A·NCT02758509·237 enrolled
Efficacy and Safety of Carvedilol in Cirrhosis Patients With Uncomplicated Ascites Without High Risk Esophageal Varices
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT05057572·104 enrolled
Beta-blockers for Prevention Of Growth Of Small Esophageal Varices In Cirrhosis: An Randomized Controlled Trial (RCT)
Completed·GGovind Ballabh Pant Hospital·N/A·NCT00772057·164 enrolled
PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?
Completed·FFederal University of São Paulo·Phase 4·NCT01893541·100 enrolled
Early Primary Prophylaxis of Esophageal Varices
Completed·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01196507·140 enrolled
Comparison of 24-hours Versus 72-hours of Octreotide Infusion in Preventing Early Rebleed From Esophageal Varices
Terminated·MMedical University of South Carolina·Phase 4·NCT03624517·34 enrolled
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Terminated·GGalectin Therapeutics Inc.·Preclinical·NCT04365868·357 enrolled
Carvedilol for Prevention of Esophageal Varices Progression
Unknown status·—·N/A·NCT03736265·240 enrolled
Anticoagulation in Gastroesophageal Varices and JAK2 Mutation
Unknown status·SShanghai Zhongshan Hospital·N/A·NCT04527666·40 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)